Metabolic Syndrome and Abnormal Peri-Organ or Intra-Organ Fat (APIFat) Deposition in Chronic Obstructive Pulmonary Disease: An Overview

Metabolites

卷:10

Dimitri P. Mikhailidis¹  Paschalis Steiropoulos²  Nikolaos Papanas³  Anca Pantea Stoian⁴  Andra I. Suceveanu⁵  Niki Katsiki⁶ 

[1] Department of Clinical Biochemistry, Royal Free Hospital campus, University College London Medical School, University College London (UCL), London NW3 2QG, UK;

[2] Department of Pneumonology, Democritus University of Thrace, 6ο km Alexandroupolis-Makris (Dragana), 68100 Alexandroupolis, Greece;

[3] Diabetes Centre, Second Department of Internal Medicine, Medical School, Democritus University of Thrace, 6ο km Alexandroupolis-Makris (Dragana), 68100 Alexandroupolis, Greece;

[4] Diabetes, Nutrition and Metabolic Diseases Department, “Carol Davila” University of Medicine, 8 Eroii Sanitari, 050474 Bucharest, Romania;

[5] Faculty of Medicine, Ovidius University, 900470 Constanta, Romania;

[6] First Department of Internal Medicine, Diabetes Center, Division of Endocrinology and Metabolism, AHEPA University Hospital, 1st Stilponos Kyriakidi, 54621 Thessaloniki, Greece;

关键词: chronic obstructive pulmonary disease;    metabolic syndrome;    metabolic markers;    non-alcoholic fatty liver disease;    epicardial fat;    non-alcoholic fatty pancreas disease;   

DOI  :  10.3390/metabo10110465

来源: DOAJ

【 摘 要 】

Chronic obstructive pulmonary disease (COPD) is a common disorder with an increasing prevalence, characterised by persistent respiratory symptoms and airflow limitation. Systemic inflammation is involved in the pathogenesis of COPD and can also predispose to metabolic disorders (e.g., metabolic syndrome (MetS) and non-alcoholic fatty liver disease (NAFLD)). Such comorbidities can negatively affect COPD outcomes, cardiovascular risk, and quality of life. Apart from NAFLD, abnormal peri-organ or intra-organ fat (APIFat) could be considered as markers for cardiometabolic diseases and even for COPD. The present narrative review considers the associations of COPD with MetS, NAFLD, and other APIFat, including epicardial, perirenal, peripancreatic, and intramuscular adipose tissue. Further research is needed to define these relationships and identify any potential clinical implications.

【 授权许可】

Unknown